Transaction cost analysis of the new drug application process: A case study of a multinational pharmaceutical company in Japan

Shota Hamada, Akiko Shibata, Hisashi Urushihara, Shintaro Sengoku, Chihiro Suematsu, Koji Kawakami

Research output: Contribution to journalArticle

Abstract

The aim of this study was to measure the transaction costs of a new drug application (NDA) process in Japan in a case study of a multinational pharmaceutical company. The NDA process was viewed as involving transactions among 3 organizations: the headquarters, the Japanese subsidiary, and the Pharmaceuticals and Medical Devices Agency. Transaction costs were calculated by multiplying the time for each transaction by an hourly wage. Work time for the NDA process totaled 14,710.6 hours and was estimated to cost US$558,000 in human resource-related expenditure in the company. The total time for intracompany transactions was 7662.5 hours (52.1% of all transactions), which was similar to that of transactions with the Pharmaceuticals and Medical Devices Agency (7048.1 hours, 47.9%). Also found was a press-and-slack procedure in time course observation. In conclusion, the current NDA system in Japan imposes a considerable time and cost burden behind that of the visible official process on a multinational company.

Original languageEnglish
Pages (from-to)371-377
Number of pages7
JournalTherapeutic Innovation and Regulatory Science
Volume48
Issue number3
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Japan
Costs and Cost Analysis
Pharmaceutical Preparations
Equipment and Supplies
Salaries and Fringe Benefits
Health Expenditures
Observation
Organizations

Keywords

  • Business analysis
  • Drug development
  • New drug application
  • Regulatory affairs
  • Transaction cost economics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Transaction cost analysis of the new drug application process : A case study of a multinational pharmaceutical company in Japan. / Hamada, Shota; Shibata, Akiko; Urushihara, Hisashi; Sengoku, Shintaro; Suematsu, Chihiro; Kawakami, Koji.

In: Therapeutic Innovation and Regulatory Science, Vol. 48, No. 3, 2014, p. 371-377.

Research output: Contribution to journalArticle

Hamada, Shota ; Shibata, Akiko ; Urushihara, Hisashi ; Sengoku, Shintaro ; Suematsu, Chihiro ; Kawakami, Koji. / Transaction cost analysis of the new drug application process : A case study of a multinational pharmaceutical company in Japan. In: Therapeutic Innovation and Regulatory Science. 2014 ; Vol. 48, No. 3. pp. 371-377.
@article{ae259d83ad8a4ab2a8f3772d021ccb48,
title = "Transaction cost analysis of the new drug application process: A case study of a multinational pharmaceutical company in Japan",
abstract = "The aim of this study was to measure the transaction costs of a new drug application (NDA) process in Japan in a case study of a multinational pharmaceutical company. The NDA process was viewed as involving transactions among 3 organizations: the headquarters, the Japanese subsidiary, and the Pharmaceuticals and Medical Devices Agency. Transaction costs were calculated by multiplying the time for each transaction by an hourly wage. Work time for the NDA process totaled 14,710.6 hours and was estimated to cost US$558,000 in human resource-related expenditure in the company. The total time for intracompany transactions was 7662.5 hours (52.1{\%} of all transactions), which was similar to that of transactions with the Pharmaceuticals and Medical Devices Agency (7048.1 hours, 47.9{\%}). Also found was a press-and-slack procedure in time course observation. In conclusion, the current NDA system in Japan imposes a considerable time and cost burden behind that of the visible official process on a multinational company.",
keywords = "Business analysis, Drug development, New drug application, Regulatory affairs, Transaction cost economics",
author = "Shota Hamada and Akiko Shibata and Hisashi Urushihara and Shintaro Sengoku and Chihiro Suematsu and Koji Kawakami",
year = "2014",
doi = "10.1177/2168479013514235",
language = "English",
volume = "48",
pages = "371--377",
journal = "Therapeutic Innovation and Regulatory Science",
issn = "2168-4790",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Transaction cost analysis of the new drug application process

T2 - A case study of a multinational pharmaceutical company in Japan

AU - Hamada, Shota

AU - Shibata, Akiko

AU - Urushihara, Hisashi

AU - Sengoku, Shintaro

AU - Suematsu, Chihiro

AU - Kawakami, Koji

PY - 2014

Y1 - 2014

N2 - The aim of this study was to measure the transaction costs of a new drug application (NDA) process in Japan in a case study of a multinational pharmaceutical company. The NDA process was viewed as involving transactions among 3 organizations: the headquarters, the Japanese subsidiary, and the Pharmaceuticals and Medical Devices Agency. Transaction costs were calculated by multiplying the time for each transaction by an hourly wage. Work time for the NDA process totaled 14,710.6 hours and was estimated to cost US$558,000 in human resource-related expenditure in the company. The total time for intracompany transactions was 7662.5 hours (52.1% of all transactions), which was similar to that of transactions with the Pharmaceuticals and Medical Devices Agency (7048.1 hours, 47.9%). Also found was a press-and-slack procedure in time course observation. In conclusion, the current NDA system in Japan imposes a considerable time and cost burden behind that of the visible official process on a multinational company.

AB - The aim of this study was to measure the transaction costs of a new drug application (NDA) process in Japan in a case study of a multinational pharmaceutical company. The NDA process was viewed as involving transactions among 3 organizations: the headquarters, the Japanese subsidiary, and the Pharmaceuticals and Medical Devices Agency. Transaction costs were calculated by multiplying the time for each transaction by an hourly wage. Work time for the NDA process totaled 14,710.6 hours and was estimated to cost US$558,000 in human resource-related expenditure in the company. The total time for intracompany transactions was 7662.5 hours (52.1% of all transactions), which was similar to that of transactions with the Pharmaceuticals and Medical Devices Agency (7048.1 hours, 47.9%). Also found was a press-and-slack procedure in time course observation. In conclusion, the current NDA system in Japan imposes a considerable time and cost burden behind that of the visible official process on a multinational company.

KW - Business analysis

KW - Drug development

KW - New drug application

KW - Regulatory affairs

KW - Transaction cost economics

UR - http://www.scopus.com/inward/record.url?scp=84905096862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905096862&partnerID=8YFLogxK

U2 - 10.1177/2168479013514235

DO - 10.1177/2168479013514235

M3 - Article

AN - SCOPUS:84905096862

VL - 48

SP - 371

EP - 377

JO - Therapeutic Innovation and Regulatory Science

JF - Therapeutic Innovation and Regulatory Science

SN - 2168-4790

IS - 3

ER -